Submit a New Drug Application for trofinetide

Delivered after the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 6 Dec 2021
Due: 30 Jun 2022
Delivered: July 2022

Deadline
Met
Late
Not met
Today

What the company said

“plans to submit a New Drug Application (NDA) around mid-year 2022”

SourceAcadia Pharmaceuticals Inc. Form 8-K press release, 2021-12-06
FilingSEC filing index
Deadline as statedaround mid-year 2022
Deadline used30 Jun 2022, the last day of the stated period
TypeRegulatory
Permanent referenceKI-C-2021-ACAD-002573
Cite as https://keptindex.org/c/KI-C-2021-ACAD-002573/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company committed to submitting the NDA by mid-year 2022 but completed the submission in July 2022, shortly after the deadline.

A
Acadia Pharmaceuticals Inc. 10-K filed 2023-02-28 Regulatory filing · published 28 Feb 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint df52dba1843c
“We submitted to the FDA a New Drug Application (NDA) for trofinetide for the treatment of Rett syndrome in July 2022” ✓ confirmed on the page

Market reaction: the shares moved +4.6% against the S&P 500 over the three sessions around the disclosure (27 Feb 2023 to 2 Mar 2023). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +946 days
Language weakened: expected → aspirational
2 versions

Version 1 · original · stated 6 Dec 2021

Deadline 30 Jun 2022 (“around mid-year 2022”) · wording expected
Version 2 · stated 18 Jul 2023

Deadline 31 Jan 2025 (“in the next 18 months”) · wording aspirational

“Acadia intends to submit a New Drug Submission (NDS) for trofinetide in Canada in the next 18 months”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Regulatory submission
Indicative materiality: High rules
Action: Submit
Deliverable: New Drug Application submission
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High
Depends on: Regulatory

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.